Literatur
- 1
André T, Boni C, Mounedji-Boudiaf L. et al .
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
N Engl J Med.
2004;
350
2343-2351
- 2
André T, Colin P, Louvet C. et al .
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered
for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results
of a randomized trial.
J Clin Oncol.
2003;
21
2896-2903
- 3
Benson A B, Schrag D, Somerfield M R. et al .
American Society of Clinical Oncology recommendations on adjuvant chemotherapy
for stage II colon cancer.
J Clin Oncol.
2004 ;
, published ahead of print in june 15, 2004 as 10.1200/JCO.2004.05.063
- 4
Bilchik A J, Saha S, Wiese D. et al .
Molecular staging of early colon cancer on the basis of sentinel lymph node
analysis: a multicenter phase II trial.
J Clin Oncol.
2001;
19
1128-1136
- 5
Cassidy J, Scheithauer W, McKendrick J. et al .
Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon
cancer (the X-ACT study): efficacy results of a phase III trial (abstr 3509).
Proc Am Soc Clin Oncol.
2004;
23
- 6
Colacchio T A, Niedzwiecki D, Compton C. et al .
Phase III trial of adjuvant immunotherapy with MOAb 17 - 1A following resection
for stage II adenocarcinoma of the colon (CALGB 9581) (abstr 3522).
Proc Am Soc Clin Oncol.
2004;
23
251
- 7
Compton C, Fenoglio-Preiser C M, Pettigrew N. et al .
American Joint Committee on Cancer prognostic factors consensus conference.
Cancer.
2000;
88
1739-1757
- 8
Elsaleh H, Powell B, Soontrapornchai P. et al .
p53 Gene mutation, microsatellite instability and adjuvant chemotherapy: impact
on survival of 288 patients with Dukes’ C Colon Carcinoma.
Oncology.
2000;
58
52-59
- 9 ESMO Guidelines Task Force .Minimal clinical recommendations. Lugano, Switzerland
2002
- 10
Francini G, Petrioli R, Lorenzini L. et al .
Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer.
Gastroenterology.
1994;
106
899-906
- 11
Grothey A, Kellermann I, Schmoll H J.
Deficits in management of patients with colorectal carcinoma in Germany: Results
of multicenter documentation of therapy algorithms.
Med Klin.
2002;
97
270-277
- 12
Haller D, Catalano J, Macdonald J S. et al .
Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer (abstract).
Proc Am Soc Clin Oncol.
1998;
17
256a
- 13
Hemminki A, Mecklin J P, Jarvinen H. et al .
Microsatellite instability is a favorable prognostic indicator in patients with
colorectal cancer receiving chemotherapy.
Gastroenterology.
2000;
119
921-928
- 14
Hermanek P J, Wiebelt H, Riedl S. et al .
Langzeitergebnisse der chirurgischen Therapie des Kolonkarzinoms.
Chirurg.
1994;
65
287-297
- 15
Hermanek P, Mansmann U, Staimmer D S. et al .
The German experience: The surgeon as a prognostic factor in colon and rectal
cancer surgery.
Surg Oncol Clin N Am.
2000;
9
33-49
- 16
International Multicenter Pooled Analysis of B2 Colon Cancer Trials (IMPACT
B2) Investigators .
Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer.
J Clin Oncol.
1999;
17
1356-1363
- 17
International Multicenter Pooled Analysis of Colon cancer trials (IMPACT) investigators
.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer.
Lancet.
1995;
345
939-944
- 18
Junginger T, Hossfeld D K, Sauer R. et al .
Adjuvante und neoadjuvante Therapie bei Kolon- und Rektumkarzinom.
Dtsch Ärztebl.
1999;
96 A
698-700
- 19
Köhne C H, Wils J, Lorenz M. et al .
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour
infusion with or without leucovorin versus bolus fluorouracil plus leuvovorin
in advanced colorectal cancer: European Organization of Research and Treatment
of Cancer Gastrointestinal Group Study 40 952.
J Clin Oncol.
2003;
21
3721-3728
- 20
Laurie J A, Moertel C G, Fleming T R. et al .
Surgical adjuvant therapy of large-bowel carcinoma. an evaluation of levamisol
and the combination of levamisol and fluorouracil: The North Central Cancer
Treatment Group and the Mayo Clinic.
J Clin Oncol.
1989;
7
1447-1456
- 21
Le Voyer T E, Sigurdson E R, Hanlon A L. et al .
Colon cancer survival is associated with increasing number of lymph nodes analyzed:
a secondary survey of Intergroup Trial INT-0089.
J Clin Oncol.
2003;
21
2912-2919
- 22
Liefers G J, Cleton-Jansen A M, van de Velde C. et al .
Micrometastasis and survival in stage II colorectal cancer.
N Engl J Med.
1998;
339
223-2288
- 23
Moertel C G, Fleming T R, Macdonald J S. et al .
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.
N Engl J Med.
1990;
322
352-358
- 24
O’Connell M J, Laurie J A, Kahn M. et al .
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients
with high-risk colon cancer.
J Clin Oncol.
1998;
16
295-300
- 25
O’Connell M J, Mailliard J A, Kahn M J. et al .
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months
as postoperative adjuvant therapy for colon cancer.
J Clin Oncol.
1997;
15
246-250
- 26
Popescu R A, Norman A, Ross P J. et al .
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years
or older.
J Clin Oncol.
1999;
17
2412-2418
- 27
Porschen R, Bermann A, Loffler T. et al .
Fluorouracil and leucovorin as effective adjuvant chemotherapy in curatively
resected stage III colon cancer.
J Clin Oncol.
2001;
19
1787-1794
- 28
Punt C J, Nagy A, Douillard J Y. et al .
Edrecolomab alone or in combination with fluorouracil and folinic acid in the
adjuvant treatment of stage III colon cancer: a randomised study.
Lancet.
2002;
360
671-677
- 29
QUASAR Collaborative Group .
Comparison of fluorouracil with additional levamisol, higher-dose folinic acid
or both as adjuvant therapy for colorectal cancer: a randomized trial.
Lancet.
2000;
355
1588-1596
- 30
Ribic C M, Sargent D J, Moore M J. et al .
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based
adjuvant chemotherapy for colon cancer.
N Engl J Med.
2003;
349
247-257
- 31
Riethmüller G, Holz E, Schlimok G. et al .
Monoclonal antibody therapy for resected Dukes‘ C colorectal cancer: seven-year
outcome of a multicenter randomized trial.
J Clin Oncol.
1998;
16
1788-1794
- 32
Rosenberg R, Hoos A, Mueller J. et al .
The prognostic significance of cytokeratin-20 RT-PCR in lymph nodes of node
negative (pN0) colorectal cancer patients.
J Clin Oncol.
2002;
20
1049-1055
- 33
Saha S, Dan A G, Berman B. et al .
Lymphazurin 1 % versus 99mTc sulfur colloid for lymphatic mapping in colorectal
tumors: a comparative analysis.
Ann Surg Oncol.
2004;
11
21-26
- 34
Saini A, Norman A R, Cunningham D. et al .
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective
as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal
cancer.
Br J Cancer.
2003;
88
1859-1865
- 35
Saltz L B, Niedzwiecki D, Hollis D. et al .
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluoroiracil/leucovorin
alone (FL) in stage III colon cancer (intergroup trial CALGB C89803) (abstr
3500).
Proc Am Soc Clin Oncol.
2004;
23
246
- 36
Sargent D J, Goldberg R M, Jacobsen S D. et al .
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly
patients.
N Engl J Med.
2001;
345
1091-1097
- 37
Sargent D J, Wieand S, Benedetti J. et al .
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint
for adjuvant colon cancer studies: Individual patient data from 12,915 patients
on 15 randomized trials (abstr 3502).
Proc Am Soc Clin Oncol.
2004;
23
246
- 38
Simpson D, Dunn C, Curran M. et al .
Oxaliplatin: a review of its use in combination therapy for advanced metastatic
colorectal cancer.
Drugs.
2003;
63
2127-2156
- 39
Sloan J A, Goldberg R M, Sargent D J. et al .
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal
cancer.
J Clin Oncol.
2002;
20
1491-1498
- 40
Staib L, Link K H, Beger H G.
Members of the Forschungsgruppe Onkologie Gastrointestinaler Tumoren (FOGT).
Toxicity and effects of adjuvant therapy in colon cancer: results of the German
prospective, controlled randomized multicenter trial FOGT-1.
J Gastrointest Surg.
2001;
5
275-281
- 41
Stoehlmacher J, Goekkurt E, Lenz H J.
Pharmacogenetic aspects in treatment of colorectal cancer - an update.
Pharmacogenomics.
2003;
4
767-777
- 42
Taal B G, Van Tinterem H, Zoetmulder F AN.
Adjuvant 5FU and levamisole in colonic and rectal cancer: improved survival
in stage II and III.
Br J Cancer.
2001;
85
1437-1443
- 43
Tsavellas G, Patel H, Allen-Mersh T G.
Detection and clinical significance of occult tumour cells in colorectal cancer.
Br J Cancer.
2001;
88
1307-1320
- 44
Watanabe T, Wu T T, Catalano P J. et al .
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
N Engl J Med.
2001;
344
1196-1206
- 45
Wolmark N, Fisher B, Rockette H. et al .
Postoperative adjuvant chemotherapy or BCG for colon cancer: results from the
NSABP protocol C-01.
J Natl Cancer Inst.
1988;
80
30-36
- 46
Wolmark N, Bryant J, Smith R. et al .
Adjuvant 5-fluorouracil and leucovorin with and without interferon alfa-2a in
colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol
C-05.
J Natl Cancer Inst.
1998;
90
1810-1816
- 47
Wolmark N, Rockette H, Mamounas E. et al .
Clinical trial to assess the relative efficacy of fluorouracil and leuovorin,
fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in
patients with Dukes‘ B and C carcinoma of the colon: results from National Surgical
Adjuvant Breast and Bowel Project C-04.
J Clin Oncol.
1999;
17
3553-3559
- 48
Wolmark N, Wieand S, Lembersky B. et al .
A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of
the colon: Results of NSABP protocol C-06 (abstract 3508).
J Clin Oncol.
2004;
22 (145)
3508
- 49
Zhou W, Goodman S N, Galizia G. et al .
Counting alleles to predict recurrence of early-stage colorectal cancer.
Lancet.
2002;
359
219-225
- 50
Zou T T, Selaru F M, Xu Y. et al .
Application of cDNA microarrays to generate a molecular taxonomy capable of
distinguishing between colon cancer and normal colon.
Oncogene.
2002;
31
4855-4862
Dr. Florian Lordick
Tumortherapiezentrum am Klinikum rechts der Isar, Technische Universität München
Ismaninger Straße 22
81675 München
Telefon: +49/89/41402095
Fax: +49/89/41404822
eMail: f.lordick@lrz.tum.de
